Evidence map›Paper›PMID 33937285›Full record

ReviewFrontiers in medicine2021

Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19.

Gaber El-Saber Batiha, Marwa A Zayed, Aya A Awad, Hazem M Shaheen, Suleiman Mustapha, Oscar Herrera-Calderon, Jorge Pamplona Pagnossa, Abdelazeem M Algammal, Muhammad Zahoor, Achyut Adhikari and 5 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Life (Basel, Switzerland) · 2023
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 9 countries.

Gaber El-Saber BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
Marwa A ZayedDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
Aya A AwadDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
Hazem M ShaheenDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
Suleiman MustaphaDepartment of Crop Protection, University of Ilorin, Ilorin, Nigeria.
Oscar Herrera-CalderonDepartment of Pharmacology, Bromatology and Toxicology, Faculty of Pharmacy and Biochemistry, Universidad Nacional Mayor de San Marcos, Lima, Peru.
Jorge Pamplona PagnossaBiological Sciences Department, Federal University of Lavras (UFLA), Lavras, Brazil.
Abdelazeem M AlgammalDepartment of Bacteriology, Immunology, and Mycology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt.
Muhammad ZahoorDepartment of Biochemistry, University of Malakand, Chakdara, Pakistan.
Achyut AdhikariCentral Department of Chemistry, Tribhuwan University, Kritipur, Nepal.
Ishan PandeyDepartment of Pathology, Motilal Nehru Medical College, Prayagraj, India.
Sara T ElazabDepartment of Pharmacology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt.
Kannan R R RengasamyGreen Biotechnologies Research Centre of Excellence, University of Limpopo, Polokwane, South Africa.
Natália Cruz-MartinsFaculty of Medicine, University of Porto, Porto, Portugal.
Helal F HettaDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Damanhour University · EGAssiut University · EGMansoura University · EGMotilal Nehru Medical College · INNational University of San Marcos · PESuez Canal University · EGTribhuvan University · NPUniversidade do Porto · PTUniversidade Federal de Lavras · BRUniversity of Ilorin · NGUniversity of Limpopo · ZAUniversity of Malakand · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrolides (e.g., erythromycin, fidaxomicin, clarithromycin, and azithromycin) are a class of bacteriostatic antibiotics commonly employed in medicine against various gram-positive and atypical bacterial species mostly related to respiratory tract infections, besides they possess anti-inflammatory and immunomodulatory effects. Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2). It was first detected in Wuhan, Hubei, China, in December 2019 and resulted in a continuing pandemic. Macrolides have been extensively researched as broad adjunctive therapy for COVID-19 due to its immunostimulant abilities. Among such class of drugs, azithromycin is described as azalide and is well-known for its ability to decrease the production of pro-inflammatory cytokines, including matrix metalloproteinases, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. In fact, a report recently published highlighted the effectiveness of combining azithromycin and hydroxychloroquine for COVID-19 treatment. Indeed, it has been underlined that azithromycin quickly prevents SARS-CoV-2 infection by raising the levels of both interferons and interferon-stimulated proteins at the same time which reduces the virus replication and release. In this sense, the current review aims to evaluate the applications of macrolides for the treatment of COVID-19.

Indexed as

azithromycinCOVID-19efficacymacrolidesSARS-CoV-2 infection

Identifiers

PMID33937285
PMCPMC8079973
OpenAlexW3156035132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.